MacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference
ROCKVILLE, Md., Dec. 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a
clinical-stage biopharmaceutical company focused on discovering and
developing innovative monoclonal antibody-based therapeutics for
the treatment of cancer, as well as autoimmune disorders and
infectious diseases, today announced that Scott Koenig, M.D.,
Ph.D., President and CEO will present at the Oppenheimer
25th Annual Healthcare Conference in New York. The
presentation will take place on Wednesday, December 10, 2014, at
3:20 p.m. Eastern Time.
A live webcast of MacroGenics' presentation may
be accessed under "Events & Presentations" in the Investor
Relations section of the Company's website at
http://ir.macrogenics.com/events.cfm. MacroGenics will maintain
an archived replay of the webcast on its website for 30 days after
the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, as well as autoimmune disorders and infectious diseases.
The Company generates its pipeline of product candidates from its
proprietary suite of next-generation antibody-based technology
platforms. The combination of MacroGenics' technology platforms and
protein engineering expertise has allowed the Company to generate
promising product candidates and enter into several strategic
collaborations with global pharmaceutical and biotechnology
companies. For more information, please see the Company's website
at www.macrogenics.com. MacroGenics is a registered trademark of
MacroGenics, Inc.
Cautionary Note on Forward-Looking
Statements
Any statements in this press release about
future expectations, plans and prospects for the Company, including
statements about the Company's strategy, future operations,
clinical development of the Company's therapeutic candidates,
milestone or opt-in payments from the Company's collaborators, the
Company's anticipated milestones and future expectations and plans
and prospects for the Company and other statements containing the
words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials,
availability and timing of data from ongoing clinical trials,
expectations for regulatory approvals, other matters that could
affect the availability or commercial potential of the Company's
product candidates and other risk factors described in the
Company's filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent the Company's views as of the date hereof. The
Company anticipates that subsequent events and developments will
cause the Company's views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date hereof.
###
CONTACT: Jim Karrels, Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com
Karen Sharma, Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com
Source:
MacroGenics, Inc.
News Provided by Acquire Media
